Novartis Intrinsic Value
NOVARTIND • Healthcare
Current Stock Price
₹1001.70
Primary Intrinsic Value
₹866.80
Market Cap
₹1202 Cr
-15.2%
Downside
Median Value
₹848.96
Value Range
₹301 - ₹1308
Assessment
Trading Above Median Value
Safety Margin
-18.0%
NOVARTIND Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹866.80 | ₹693.44 - ₹1040.16 | -13.5% | EPS: ₹39.40, Sector P/E: 22x |
| Book Value Method | asset | ₹1308.33 | ₹1177.50 - ₹1439.16 | +30.6% | Book Value/Share: ₹654.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹645.00 | ₹580.50 - ₹709.50 | -35.6% | Revenue/Share: ₹322.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1141.67 | ₹1027.50 - ₹1255.84 | +14.0% | EBITDA: ₹137.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹848.96 | ₹679.17 - ₹1018.75 | -15.2% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹300.51 | ₹270.46 - ₹330.56 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹582.82 | ₹524.54 - ₹641.10 | -41.8% | Revenue Growth: -2.8%, Adj P/E: 14.8x |
| ROE Based Valuation | profitability | ₹970.00 | ₹873.00 - ₹1067.00 | -3.2% | ROE: 12.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹761.52 | ₹685.37 - ₹837.67 | -24.0% | EPS: ₹39.40, BVPS: ₹654.17 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
NOVARTIND Intrinsic Value Analysis
What is the intrinsic value of NOVARTIND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Novartis (NOVARTIND) is ₹848.96 (median value). With the current market price of ₹1001.70, this represents a -15.2% variance from our estimated fair value.
The valuation range spans from ₹300.51 to ₹1308.33, indicating ₹300.51 - ₹1308.33.
Is NOVARTIND undervalued or overvalued?
Based on our multi-method analysis, Novartis (NOVARTIND) appears to be trading above median value by approximately 15.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 35.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.41x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Novartis
Additional stock information and data for NOVARTIND
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹75 Cr | ₹74 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹113 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹45 Cr | ₹-32 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹39 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-69 Cr | ₹-69 Cr | Negative Cash Flow | 3/10 |